SUGGESTED READING
On KS
Bower M, Weir J, Francis N, et al: The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS 23:1701–1706, 2009.
Housri N, Yarchoan R, Kaushal A: Radiotherapy for patients with the human immunodeficiency virus: Are special precautions necessary? Cancer 116:273–283, 2010.
Martellotta F, Berretta M, Vaccher E, et al: AIDS-related Kaposi's sarcoma: State of the art and therapeutic strategies. Curr HIV Res 7:634–638, 2009.
Shiels MS, Pfeiffer RM, Hall HI, et al: Proportion of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 305:1450–1459, 2011.
Sullivan RJ, Pantanowitz L: New drug targets in Kaposi sarcoma. Expert Opin Ther Targets 14:1355–1366, 2010.
Sullivan RJ, Pantanowitz L, Casper C, et al: HIV/AIDS: Epidemiology, pathophysiology and treatment of Kaposi sarcoma-associated herpes virus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 47:1209–1215, 2008.
On NHL
Bateganya MH, Stanaway J, Brentlinger PE, et al: Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: A retrospective study on the impact of HIV infection and its treatment. J Acquir Immune Defic Syndr 56:312–319, 2011.
Guech-Ongey M, Simard EP, Anderson WF, et al: AIDS-related Burkitt lymphoma in the United States: What do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 116:5600–5604, 2010.
Levine AM: HIV-associated lymphoma. Blood 115:2986–2987, 2010.
Montoto S, Wilson J, Shaw K, et al: Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS 24:851–856, 2010.
Re A, Michieli M, Casari S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: Long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 114:1306–1313, 2009.
Sparano JA, Lee JY, Kaplan LD, et al: Rituximab(Drug information on rituximab) plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin's lymphoma. Blood 115:3008–3016, 2010.
On cervical and anal carcinomas
Chaturvedi AK, Madeleine MM, Biggar RJ, et al: Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 101:1120–1130, 2009.
Einstein MH, Phaëton R: Issues in cervical cancer incidence and treatment in HIV. Curr Opin Oncol 22:449–455, 2010.
Franceschi S, Ronco G: The prevention of cervical cancer in HIV-infected women. AIDS 24:2579–2580, 2010.
Fraunholz I, Rabeneck D, Gerstein J, et al: Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin(Drug information on mitomycin) C for anal carcinoma: Are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol 98:99–104, 2011.
Hauerstock D, Ennis RD, Grossbard M, et al: Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. Clin Colorectal Cancer 9:238–242, 2010.
Lam JM, Hoch JS, Tinmouth J, et al: Cost-effectiveness of screening for anal precancers in HIV-positive men. AIDS 25:635–642, 2011.
On non–AIDS-defining malignancies
Deeken JF, Pantanowitz L, Dezube BJ: Targeted therapies to treat non-AIDS defining cancers in patients with HIV on HAART therapy: Treatment considerations and research outlook. Curr Opin Oncol 21:445–454, 2009.
Franceschi S, Lise M, Clifford GM, et al: Changing patterns of cancer incidence in the early- and late-HAART periods: The Swiss HIV Cohort Study. Br J Cancer 103:416–422, 2010.
Krishnan S, Schouten JT, Jacobson DL, et al: Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: An ACTG longitudinal linked randomized trials analysis. Oncology 80:42–49, 2011.
Seaberg EC, Wiley D, Martínez-Maza O, et al: Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 116:5507–5516, 2010.
Shiels MS, Pfeiffer RM, Gail MH, et al: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103:753–762, 2011.
Simard EP, Pfeiffer RM, Engels EA: Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 117:1089–1096, 2011.
Acknowledgment
Supported, in part, by grants from the California HIV/AIDS Research Program, the UCLA Network for AIDS Research in Los Angeles (MC08-LA-710) and USPHS, NIH grants AI-69424, AI28697, CA-121947, and RR00865.
Abbreviations in this chapter
ACTG = AIDS Clinical Trials Group; AMC = AIDS Malignancy Consortium; ANRS = Agence Nationale de Recherche sur le Sida et les Hépatites Virales; FDA = US Food and Drug Administration; FIGO = International Federation of Gynecology and Obstetrics; SEER = Surveillance, Epidemiology and End Results
